Literature DB >> 1391681

Pharmacokinetics and metabolism of codeine in humans.

T B Vree1, C P Verwey-van Wissen.   

Abstract

Codeine (30 mg phosphate) was metabolized by eight human volunteers to the following six metabolites: codeine-6-glucuronide 81.0 +/- 9.3 per cent, norcodeine 2.16 +/- 1.44 per cent, morphine 0.56 +/- 0.39 per cent, morphine-3-glucuronide 2.10 +/- 1.24 per cent, morphine-6-glucuronide 0.80 +/- 0.63 per cent, and normorphine 2.44 +/- 2.42 per cent. Two out of eight volunteers were unable to O-dealkylate codeine into morphine and lack therefore the cytochrome P450 IID6 isoenzyme. The half-life of codeine was 1.47 +/- 0.32 h, that of codeine-6-glucuronide 2.75 +/- 0.79 h, and that of morphine-3-glucuronide 1.71 +/- 0.51 h. The systemic clearance of codeine was 2280 +/- 840 ml min-1, the renal clearance of codeine was 93.8 +/- 29.8 ml min-1, and that of codeine-6-glucuronide was 122 +/- 39.2 ml min-1. The plasma AUC of codeine-6-glucuronide is approximately 10 times higher than that of codeine. Protein binding of codeine and codeine-6-glucuronide in vivo was 56.1 +/- 2.5 per cent and 34.0 +/- 3.6 per cent, respectively. The in vitro protein binding of norcodeine was 23.5 +/- 2.9 per cent; of morphine, 46.5 +/- 2.4 per cent; of normorphine, 23.5 +/- 3.5 per cent; of morphine-3-glucuronide, 27.0 +/- 0.8 per cent; and of morphine-6-glucuronide, 36.7 +/- 3.8 per cent.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1391681     DOI: 10.1002/bdd.2510130607

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  20 in total

1.  Analgesic and immunomodulatory effects of codeine and codeine 6-glucuronide.

Authors:  V Srinivasan; D Wielbo; J Simpkins; J Karlix; K Sloan; I Tebbett
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

Review 2.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

3.  Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions.

Authors:  Michel Tod; Sylvain Goutelle; Fannie Clavel-Grabit; Grégoire Nicolas; Bruno Charpiat
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

4.  Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure.

Authors:  Sarah Badaoui; Ashley M Hopkins; A David Rodrigues; John O Miners; Michael J Sorich; Andrew Rowland
Journal:  AAPS J       Date:  2021-01-06       Impact factor: 4.009

5.  Long-term tracking of opioid consumption in two United States cities using wastewater-based epidemiology approach.

Authors:  Adam J Gushgari; Arjun K Venkatesan; Jing Chen; Joshua C Steele; Rolf U Halden
Journal:  Water Res       Date:  2019-06-03       Impact factor: 11.236

Review 6.  Codeine and opioid metabolism: implications and alternatives for pediatric pain management.

Authors:  Vidya Chidambaran; Senthilkumar Sadhasivam; Mohamed Mahmoud
Journal:  Curr Opin Anaesthesiol       Date:  2017-06       Impact factor: 2.706

7.  Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects.

Authors:  Eloise A Gelston; Janet K Coller; Olga V Lopatko; Heather M James; Helmut Schmidt; Jason M White; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

8.  Aromatase and 5-alpha reductase gene expression: modulation by pain and morphine treatment in male rats.

Authors:  Anna Maria Aloisi; Ilaria Ceccarelli; Paolo Fiorenzani; Melinda Maddalena; Alessandra Rossi; Valentina Tomei; Giuseppina Sorda; Barbara Danielli; Michele Rovini; Andrea Cappelli; Maurizio Anzini; Antonio Giordano
Journal:  Mol Pain       Date:  2010-10-26       Impact factor: 3.395

Review 9.  Cytochrome P450-activated prodrugs.

Authors:  Paul R Ortiz de Montellano
Journal:  Future Med Chem       Date:  2013-02       Impact factor: 3.808

10.  O-demethylation of codeine to morphine inhibited by low-dose levomepromazine.

Authors:  M Vevelstad; S Pettersen; C Tallaksen; O Brørs
Journal:  Eur J Clin Pharmacol       Date:  2009-03-24       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.